| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 09/05/2024 | 13:53 | IH Market News | Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 08/05/2024 | 13:00 | Business Wire | Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 08/05/2024 | 12:30 | Business Wire | Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 03/05/2024 | 00:30 | Business Wire | Teva to Present at the 2024 Bank of America Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 02/05/2024 | 14:30 | Business Wire | Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 30/04/2024 | 10:00 | Business Wire | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 16/04/2024 | 23:43 | Business Wire | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 16/04/2024 | 14:00 | Business Wire | Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 11/04/2024 | 14:30 | Business Wire | Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 09/04/2024 | 22:30 | Business Wire | Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/04/2024 | 19:00 | Business Wire | New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 04/04/2024 | 14:30 | Business Wire | Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 01/04/2024 | 14:30 | Business Wire | Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 07/03/2024 | 22:27 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 05/03/2024 | 22:43 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 26/02/2024 | 13:00 | Business Wire | Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 24/02/2024 | 02:15 | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 24/02/2024 | 02:15 | Business Wire | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 20/02/2024 | 14:30 | Business Wire | Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 13/02/2024 | 15:05 | IH Market News | Hotter-Than-Expected Inflation Data Likely To Weigh On Wall Street | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 12/02/2024 | 23:03 | IH Market News | Dow Reaches New Record Closing High But Nasdaq, S&P 500 Give Back Ground | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 12/02/2024 | 15:13 | IH Market News | Teva Pharmaceutical, Urban Outfitters Upgraded | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 31/01/2024 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 31/01/2024 | 13:00 | Business Wire | Teva Reports Growth in Fourth Quarter and Full Year 2023 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 31/01/2024 | 12:00 | Business Wire | Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 02/01/2024 | 22:30 | Business Wire | Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 02/01/2024 | 14:50 | Dow Jones News | Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 28/12/2023 | 22:30 | Business Wire | Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 14/12/2023 | 14:30 | Business Wire | Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/12/2023 | 17:19 | Business Wire | Neue Post-Hoc-Analyse von Phase-3-Daten zeigt, dass AJOVY® (Fremanezumab) Migräneattacken bei Erwachsenen mit Migräne und komorbider Adipositas reduziert | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |